For the full year ended December 2025, revenue was 173.14 billion yen (up 9.3% YoY), operating income was 3.213 billion yen (down 19.7% YoY), supported by strong sales of the flagship product Iceuili.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2160","jir_company_name":"GNI Group, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-26","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/2160-20260326-01.pdf","jir_short_summary":"For the full year ended December 2025, revenue was 173.14 billion yen (up 9.3% YoY), operating income was 3.213 billion yen (down 19.7% YoY), supported by strong sales of the flagship product Iceuili.","jir_summary":"### Overview of Performance\nFor the full year ended December 2025, revenue reached 17,314 million yen (up 9.3% YoY), contributed by strong sales of the flagship product Iceuili, achieving record-high monthly sales (December) as well as quarterly and cumulative sales. Meanwhile, operating income was 3,213 million yen (down 19.7% YoY). The pharmaceutical segment continued to post operating losses, particularly impacted by increased R&D expenses and listing preparation costs associated with clinical trial progress in Australia.\n\n### Business Composition and Future Outlook\nAs a global biopharmaceutical company, it operates three businesses: pharmaceuticals, drug discovery, and medical devices. It is expanding its operations mainly in China and the U.S., with plans to make Gyre Therapeutics a wholly owned subsidiary of Cullgen in early Q2 2026. Although the Japan headquarters remains in deficit, efforts are focused on establishing a stable earnings base and diversifying profit sources away from U.S. and China. Priority is given to preparing NDA submission for F351, expecting growth from 2026 onward.","jir_financial_highlights":"Revenue: 17,314 million yen (Up 9.3% YoY)\nOperating Income: 3,213 million yen (Down 19.7% YoY)\nPharmaceutical Business Revenue: 789 million yen (Down 45.2% YoY)\nPharmaceutical Business Operating Income: \u25b33,958 million yen (Unknown)","jir_category":"","jir_hashtags":"#GNIGroup, #FinancialResultsPresentation, #Biopharmaceuticals","jir_key_figures":"Full Year Revenue: 17,314 million yen (up 9.3% YoY)\nFull Year Operating Income: 3,213 million yen (down 19.7% YoY)\nPharmaceutical Business Operating Loss: \u25b33,958 million yen (cumulative for 2025)","jir_meta_title":"GNI Group Full Year Financial Results for Fiscal Year Ending December 2025: Revenue 17,314 Million Yen, Operating Income 3,213 Million Yen","jir_meta_description":"GNI Group's full year financial results for the fiscal year ending December 2025. Revenue reached 17,314 million yen (up 9.3% YoY) while operating income was 3,213 million yen (down 19.7% YoY). Strong sales of the flagship product Iceuili contributed.","jir_og_title":"GNI Group Financial Results Presentation for Fiscal Year Ending December 2025","jir_og_description":"Revenue for 2025 was 17,314 million yen and operating income was 3,213 million yen. Explanation of strong flagship product sales alongside impact of increased R&D expenses.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue Trend (FY2015-2025)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2015\\\",\\\"2016\\\",\\\"2017\\\",\\\"2018\\\",\\\"2019\\\",\\\"2020\\\",\\\"2021\\\",\\\"2022\\\",\\\"2023\\\",\\\"2024\\\",\\\"2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue (million yen)\\\",\\\"data\\\":[1016,1306,2648,5018,7446,9773,12690,17418,26010,23611,26840],\\\"backgroundColor\\\":\\\"#003366\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (FY2015-2025)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2015\\\",\\\"2016\\\",\\\"2017\\\",\\\"2018\\\",\\\"2019\\\",\\\"2020\\\",\\\"2021\\\",\\\"2022\\\",\\\"2023\\\",\\\"2024\\\",\\\"2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income (million yen)\\\",\\\"data\\\":[-3471,1402,1377,1624,1869,1302,1502,13108,3753,4003,3213],\\\"backgroundColor\\\":\\\"#99CCFF\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"FY2025 Revenue Composition by Business Segment\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceuticals\\\",\\\"Drug Discovery\\\",\\\"Medtech\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"data\\\":[64,3,28,4],\\\"backgroundColor\\\":[\\\"#003366\\\",\\\"#3399FF\\\",\\\"#FF9933\\\",\\\"#CCCCCC\\\"]}]}}\"}]","ir_related_company":9370,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-36684","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n